A patent currently prevents any generic Nasonex from being manufactured in the United States. The patent is not set to expire until July 2014. This is the earliest date that a generic version could become available. However, patents for specific uses of the drug or lawsuits could extend this exclusivity period past 2014.
Nasonex® (mometasone nasal spray) is a prescription nasal spray used to treat nasal allergies (known medically as allergic rhinitis) and nasal polyps. It belongs to a group of medications known as corticosteroids (or simply "steroids" for short).
Nasonex is manufactured by Schering-Plough Corporation. It is currently under the protection of a patent that prevents any generic Nasonex from being manufactured in the United States.
When Will a Generic Version Be Available?
The first patent for Nasonex currently expires in July 2014. This is the earliest possible date that a generic version of Nasonex could become available. However, there are circumstances that could come up to extend the exclusivity period of Nasonex beyond 2014. This could include things such as other patents for specific Nasonex uses or lawsuits.
Once Nasonex goes off patent, there may be several companies that manufacture a generic Nasonex product.
Is Mometasone a Generic Nasonex?
No, it isn't. Mometasone is the active ingredient in Nasonex (as well as other medications), but it is not a generic version of Nasonex. What can be confusing is that, oftentimes, the active ingredient of a drug is referred to as the "generic name."
The generic name is different than a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off patent, and another company (besides the original manufacturer) would make the product.